Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
TransUnion is a consulting services business based in the US. TransUnion shares (TRU) are listed on the NYSE and all prices are listed in US Dollars. TransUnion employs 8,200 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$116.84|
|52-week range||$77.76 - $125.35|
|50-day moving average||$120.11|
|200-day moving average||$106.96|
|Wall St. target price||$132.29|
|Dividend yield||$0.34 (0.29%)|
|Earnings per share (TTM)||$2.40|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-17)||0.65%|
|1 month (2021-08-24)||-1.53%|
|3 months (2021-06-24)||5.91%|
|6 months (2021-03-24)||32.25%|
|1 year (2020-09-23)||45.32%|
|2 years (2019-09-23)||44.21%|
|3 years (2018-09-21)||57.19%|
|5 years (2016-09-23)||246.19%|
Valuing TransUnion stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of TransUnion's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
TransUnion's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 48x. In other words, TransUnion shares trade at around 48x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
TransUnion's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.3225. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into TransUnion's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
TransUnion's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 billion.
The EBITDA is a measure of a TransUnion's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$2.9 billion|
|Operating margin TTM||24.54%|
|Gross profit TTM||$1.8 billion|
|Return on assets TTM||6.2%|
|Return on equity TTM||18.46%|
|Market capitalisation||$22.2 billion|
TTM: trailing 12 months
There are currently 1.9 million TransUnion shares held short by investors – that's known as TransUnion's "short interest". This figure is 0.4% up from 1.9 million last month.
There are a few different ways that this level of interest in shorting TransUnion shares can be evaluated.
TransUnion's "short interest ratio" (SIR) is the quantity of TransUnion shares currently shorted divided by the average quantity of TransUnion shares traded daily (recently around 687789.05109489). TransUnion's SIR currently stands at 2.74. In other words for every 100,000 TransUnion shares traded daily on the market, roughly 2740 shares are currently held short.
However TransUnion's short interest can also be evaluated against the total number of TransUnion shares, or, against the total number of tradable TransUnion shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TransUnion's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 TransUnion shares in existence, roughly 10 shares are currently held short) or 0.0099% of the tradable shares (for every 100,000 tradable TransUnion shares, roughly 10 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against TransUnion.
Find out more about how you can short TransUnion stock.
Dividend payout ratio: 9.77% of net profits
Recently TransUnion has paid out, on average, around 9.77% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.32% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), TransUnion shareholders could enjoy a 0.32% return on their shares, in the form of dividend payments. In TransUnion's case, that would currently equate to about $0.34 per share.
While TransUnion's payout ratio might seem low, this can signify that TransUnion is investing more in its future growth.
TransUnion's most recent dividend payout was on 8 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 23 August 2021 (the "ex-dividend date").
Over the last 12 months, TransUnion's shares have ranged in value from as little as $77.7625 up to $125.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while TransUnion's is 1.3221. This would suggest that TransUnion's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
TransUnion provides risk and information solutions. The company operates in three segments: U. S. Markets, International, and Consumer Interactive. The U. S. Markets segment provides consumer reports, actionable insights, and analytics, such as credit and other scores, as well as technology solutions for businesses.
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Sep. 20, 2021
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.